Women's Hormone Therapy & Menopause Treatment in Sarasota, Lakewood Ranch & Bradenton

Bioidentical hormones are structurally identical to the hormones your body produces naturally. They are derived from plant sources and then modified to match human hormone molecules exactly. Synthetic hormones, like medroxyprogesterone acetate (Provera) or conjugated equine estrogens (Premarin), have different molecular structures and carry different risk profiles. The Women's Health Initiative study that raised concerns about hormone therapy in 2002 used synthetic hormones, not bioidenticals. Subsequent research has shown that bioidentical estradiol and progesterone have a more favorable safety profile, particularly regarding breast cancer and cardiovascular risk.

The optimal time to start depends on your symptoms, lab results, and individual risk factors. Many women benefit from progesterone support during early perimenopause, sometimes years before estrogen replacement becomes necessary. For women already in menopause, current evidence supports starting hormone therapy within 10 years of menopause onset for the best risk-benefit profile, particularly for cardiovascular and bone protection. Ryan Hentges, NP evaluates your complete picture and discusses timing as part of your initial consultation.

This question traces back to the 2002 WHI study, which used synthetic conjugated equine estrogens and medroxyprogesterone. Those synthetic compounds do carry different risks than bioidentical hormones. Research published since 2002 indicates that bioidentical estradiol combined with bioidentical progesterone has a substantially lower breast cancer risk compared to synthetic hormone combinations. That said, individual risk factors including family history, breast density, and genetic markers are all evaluated before prescribing. Ryan Hentges, NP discusses the evidence and your personal risk profile in detail before starting therapy.

Testosterone is not just a male hormone. Women produce testosterone in the ovaries and adrenal glands, and it plays a direct role in libido, energy, mood, motivation, muscle maintenance, and cognitive function. Testosterone levels in women decline gradually starting in the late 20s and drop further during perimenopause and menopause. By post-menopause, many women are producing a fraction of their peak testosterone output. Low-dose bioidentical testosterone, carefully monitored through lab work, can address symptoms that estrogen and progesterone alone do not fully resolve.

Women who have had a hysterectomy do not need progesterone for uterine protection, which simplifies the protocol in one respect. However, hysterectomy, particularly when combined with oophorectomy (ovary removal), causes an abrupt hormonal drop that often produces more severe symptoms than natural menopause. Estradiol and testosterone replacement become especially relevant in this scenario. Ryan Hentges, NP adjusts the protocol based on whether ovaries were preserved or removed and how your labs present at the time of evaluation.

Hormonal decline contributes to weight gain through multiple mechanisms: declining estrogen shifts fat storage toward the abdomen, reduced testosterone impairs muscle metabolism, thyroid changes slow metabolic rate, and insulin resistance tends to worsen during the menopausal transition. Restoring hormonal balance may help support improved body composition, but hormone therapy is not a weight loss drug. For women whose weight concerns involve significant metabolic dysfunction, Ryan Hentges, NP may recommend combining hormone optimization with a medical weight management protocol for the most comprehensive approach.

Current evidence supports individualized duration decisions rather than arbitrary time limits. The outdated practice of stopping HRT after 5 years was based on the 2002 WHI data using synthetic hormones. More recent research suggests that for many women, the benefits of bioidentical hormone therapy, including bone protection, cardiovascular support, and cognitive health, continue as long as therapy is maintained. Ryan Hentges, NP reassesses risk and benefit at each follow-up and discusses duration as an ongoing conversation, not a fixed endpoint.

Thyroid dysfunction and menopause overlap in timing and symptoms, which is why thyroid labs are included on every panel at iRevive. Hashimoto's thyroiditis, the most common cause of hypothyroidism, disproportionately affects women and often surfaces or worsens during perimenopause. Symptoms like fatigue, weight gain, brain fog, and depression can be caused by thyroid dysfunction, hormonal decline, or both. Treating one without evaluating the other leaves gaps in the clinical picture. iRevive tests TSH, free T3, free T4, and thyroid antibodies to catch what a standard TSH-only test would miss.